A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer
Context Prediction of high probability of survival from standard cancer treatments is
fundamental for individualized cancer treatment strategies. Objective To develop a predictor
of response and survival from chemotherapy for newly diagnosed invasive breast cancer.
Design, Setting, and Patients Prospective multicenter study conducted from June 2000 to
March 2010 at the MD Anderson Cancer Center to develop and test genomic predictors for
neoadjuvant chemotherapy. Patients were those with newly diagnosed ERBB2 (HER2 or …
fundamental for individualized cancer treatment strategies. Objective To develop a predictor
of response and survival from chemotherapy for newly diagnosed invasive breast cancer.
Design, Setting, and Patients Prospective multicenter study conducted from June 2000 to
March 2010 at the MD Anderson Cancer Center to develop and test genomic predictors for
neoadjuvant chemotherapy. Patients were those with newly diagnosed ERBB2 (HER2 or …